Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) issued its earnings results on Tuesday. The company reported ($2.00) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($2.19), Zacks reports. The business had revenue of $314.39 million for the quarter, compared to the consensus estimate of $303.21 million. Guardian Pharmacy Services updated its FY 2024 guidance to EPS.
Guardian Pharmacy Services Stock Up 1.2 %
Guardian Pharmacy Services stock traded up $0.26 during midday trading on Friday, reaching $21.26. The stock had a trading volume of 21,129 shares, compared to its average volume of 155,695. Guardian Pharmacy Services has a twelve month low of $14.16 and a twelve month high of $23.05.
Insider Activity
In other Guardian Pharmacy Services news, Director Thomas J. Salentine, Jr. bought 35,714 shares of Guardian Pharmacy Services stock in a transaction on Friday, September 27th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $499,996.00. Following the completion of the purchase, the director now directly owns 35,714 shares of the company’s stock, valued at $499,996. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Analysts Set New Price Targets
Read Our Latest Report on Guardian Pharmacy Services
Guardian Pharmacy Services Company Profile
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
Recommended Stories
- Five stocks we like better than Guardian Pharmacy Services
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Top-Performing Non-Leveraged ETFs This Year
- Energy and Oil Stocks Explained
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Differences Between Momentum Investing and Long Term Investing
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.